Evidence map›Paper›PMID 41179110›Full record

ArticleERJ open research2025

Clinically important deterioration in a mild-moderate COPD population.

Sharmistha Biswas, Dany Doiron, Pei Zhi Li, Shawn D Aaron, Kenneth R Chapman, Paul Hernandez, François Maltais, Darcy D Marciniuk, Denis O'Donnell, Don D Sin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sharmistha BiswasRespiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Dany DoironRespiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Pei Zhi LiRespiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Shawn D AaronThe Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Kenneth R ChapmanAsthma and Airway Centre, University Health Network and University of Toronto, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-2498-9859
Paul HernandezFaculty of Medicine, Division of Respirology, Dalhousie University, Halifax, NS, Canada.
François MaltaisInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada.ORCID https://orcid.org/0000-0002-6809-4651
Darcy D MarciniukRespiratory Research Centre, University of Saskatchewan, Saskatoon, SK, Canada.
Denis O'DonnellDept of Medicine/Physiology, Queens University, Kingston, ON, Canada.ORCID https://orcid.org/0000-0001-7593-2433
Don D SinCentre for Heart Lung Innovation, Dept of Medicine, University of British Columbia, Vancouver, BC, Canada.
Brandie WalkerDivision of Respirology, Dept of Medicine, University of Calgary, Calgary, AB, Canada.
Gilbert NadeauGSK, Mississauga, ON, Canada.
Chris ComptonRespiratory Medical Franchise, GSK, Brentford, UK.
Wan C TanCentre for Heart Lung Innovation, Dept of Medicine, University of British Columbia, Vancouver, BC, Canada.
Jean BourbeauRespiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.ORCID https://orcid.org/0000-0002-7649-038X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Clinically important deterioration (CID), a composite of exacerbation, declines in lung function and health status has been studied as an indicator of disease worsening in moderate-severe COPD clinical populations. We assessed whether CID is predictive of worsening over 18 months in a population-based mild-moderate COPD cohort. Methods: Canadian Cohort Obstructive Lung disease (CanCOLD) participants with COPD were assessed over 18 months for CID, and over the next 18 months for outcomes. Their association was then examined: 1) defined into threshold-based binary variables, the declines in forced expiratory volume in 1 s (FEV Results: Out of 420 participants, 252 (60%) demonstrated CID (definition 1, St George's Respiratory Questionnaire (SGRQ)). Presence of CID at 18 months showed association with future moderate/severe exacerbation (not statistically significant), worsening health status (COPD Assessment Test (CAT) score), and dyspnoea. As a component, FEV Discussion: Our finding of informative CID components seems to support recommendations of emphasis on exacerbation history and health status, over severity of airway obstruction in clinical assessments to predict outcomes. Suitable adaptations of the current CID definition may be needed for mild-moderate COPD populations.

Identifiers

PMID41179110
PMCPMC12572958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.